Vincerx Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VINC research report →
Range $2 – $4
Price Chart
About the company
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U. S.
- CEO
- Raquel E. Izumi
- IPO
- 2020
- Employees
- 13
- HQ
- Palo Alto, CA, US
Get TickerSpark's AI analysis on VINC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $78.51K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.03
- EV/EBITDA
- 0.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -431.29%
- ROIC
- -1155.03%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,090,000-19.1%
- Op Income
- $-31,463,000
- Net Income
- $-30,074,000+25.1%
- EPS
- $-5.75+15.9%
- OCF Growth
- +35.4%
- FCF Growth
- +35.4%
- 52W High
- $1.43
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.03
- Beta
- 1.46
- RSI (14)
- 55
- Avg Volume
- 5.08K
No earnings-call transcripts are available for VINC yet.
- Free Float
- 90.7%
- Shares Outstanding
- 5.23M
- Float Shares
- 4.75M
of shares held by institutions
26 13F filers
Buy/sell ratio 1.09. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 47.08K | 0 |
| Wade G W & Inc | 10.90K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 20, 24 | Haas Kevin | other | 0 |
| Dec 20, 24 | Haas Kevin | other | 27,875 |
| Aug 12, 24 | THOMAS TOM C | other | 175,000 |
| Aug 12, 24 | THOMAS TOM C | other | 31,250 |
| Aug 12, 24 | THOMAS TOM C | other | 93,750 |
| Aug 12, 24 | THOMAS TOM C | other | 86,000 |
| Aug 12, 24 | THOMAS TOM C | other | 58,000 |
| Aug 12, 24 | THOMAS TOM C | other | 56,000 |
| Aug 12, 24 | THOMAS TOM C | other | 55,250 |
| Aug 12, 24 | THOMAS TOM C | sell | 86,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VINC coverage
Recent articles, reports, and earnings notes.
No research on VINC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VINC report →